Recuro Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.60 M
- Paid Up Capital ₹ 2.60 M
- Company Age 13 Year, 4 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 5.00 M
- Revenue Growth %
- Profit Growth -27.53%
- Ebitda -165.73%
- Net Worth -39.52%
- Total Assets -10.32%
About Recuro Pharma
Recuro Pharma Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 12 September 2011 and has a history of 13 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Corporate was formerly known as Abhay Sai Pharma Labs Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 2.60 M and a paid-up capital of Rs 2.60 M.
The company currently has active open charges totaling ₹5.00 M.
Mrutyumjaya Penumanchili and Saisakuntala Pandi serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24233TG2011PTC076482
-
Company No.
076482
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
12 Sep 2011
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Recuro Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mrutyumjaya Penumanchili
|
Director | 12-Sep-2011 | Current |
|
Saisakuntala Pandi
|
Director | 12-Sep-2011 | Current |
Financial Performance of Recuro Pharma.
Recuro Pharma Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 27.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 39.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recuro Pharma?
In 2020, Recuro Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.00 M
₹0
Charges Breakdown by Lending Institutions
- Andhra Bank : 0.50 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Dec 2015 | Andhra Bank | ₹5.00 M | Open |
How Many Employees Work at Recuro Pharma?
Unlock and access historical data on people associated with Recuro Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recuro Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recuro Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.